Janssen outlines ambitious plans for future product launches

Janssen has outlined its plans for future product launches and regulatory submissions during a pharmaceutical business review meeting organised by parent company Johnson and Johnson.

Speaking to industry analysts, the company confirmed that it will be launching or filing for regulatory approval of more than ten new products with blockbuster potential between 2017 and 2021, as well as more than 50 line extensions of existing and new medicines.

The company will also seek to drive further sustainable growth by leveraging its strong portfolio of core blockbuster products and the productivity of its innovation model, as well as the benefits offered by its acquisition of the biotech company Actelion.

Alex Gorsky, chairman and chief executive officer of Johnson and Johnson, said: "With a growing core business of differentiated medicines and a strong line-up of innovative products expected to launch or file over the next five years, we are leading the industry in advancing the health of patients around the world."

Since 2011, Janssen has received US approval for 11 new molecular entities, with a portfolio focused on five core therapeutic areas – immunology, infectious diseases and vaccines, neuroscience, cardiovascular and metabolism, and oncology.

A sixth therapeutic area – pulmonary arterial hypertension – will be added upon the completion of the Actelion deal, which is expected to take place before the end of the second quarter.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.